an inflammatory skin reaction. The cellular interactions and the mechanisms that govern them in the development of both allergic and irritant contact dermatitis form the focus of this review.
Epidermal immunocompetent Ceils
To understand the pathogenetic mechanisms involved in contact dermatitis, it is important to appreciate the different immunocompetent cells ofthe skin. The epidermis represents the outermost boundary of the immune system and is composed mainly of keratinocytes, Langerhans cells, and melanocytes. Keratinocytes and Langerhans cells are known to be immunocompetent; however, the immunologic function of melanocytes, if any, is not clear.
The keratinocyte's role in the immunoregulation ofthe skin has only recently been appreciated. The first indication of its immunocompetent nature was the unexpected discovery in the early 1980s by Luger et al. and Sauder et al. of a keratinocyte-derived cytokine, epidermal cell-derived thymocyte activating factor (ETAF).'-The majority of ETAF activity was later found to be due to interleukin-1 (IL-1). As keratinocytes were investigated more widely, it became clear that activated keratinocytes have the ability to produce a variety of distinct T-cell-activating and growth-stimulating cytokines.^" Others include interleukin-3 (IL-3),^''' granulocyte macrophage colony stimulating factor (GM-CSF),^ epidermal cell-derived natural killer cell activating factor (ENKAF),** and interleukin-6 (IL-e).*Î n addition to these growth-promoting and activating cytokines, keratinocytes also synthesize T-cell inhibitory cytokines and factors. These include epidermal cell-derived lymphocyte differentiation inhibiting factor,'" keratinocyte lymphocyte inhibitory factor,"'ê icosanoids,'^"'^ IL-I inhibitor,"' and transforming growth factor beta.'^ As well as T-cell stimulatoi-y and inhibitory factors, keratinocytes also elaborate mono- nuclear cell chemotactic factors, which are not well characterized.'^ The actions of some of these epidermal factors and cytokines as they may relate to contact dermatitis are introduced briefly below. Since its discovery, interleukin-1 has been widely investigated. Epidermal IL-1 release can be induced by specific stimuli, (eg, antigen'^) or by traumatic epidermal injury, (eg, irritant and/or ultraviolet [UV] irradiation""^'). Interleukin-1 can enhance an immune response directly by inducing T-cell activation and proliferation,^^ and indirectly by inducing the secretion of GM-CSF.^' Interleukin-6 acts synergistically with IL-1 in T-cell activation, and its release may thereby enhance IL-1 -induced T-cell proliferation and lymphokine release. ' In contrast to the growth stimulatory cytokines, both ELDIF and KLIF inhibit T-cell proliferation and IL-2 production.'°"'^ Keratinocyte lymphocyte inhibitory factor may be a composite of different cytokines, including TGF-beta, since KLIF's inhibitory effect is partially reversible by an antibody against TGFbeta.'^'^'' Eicosanoids, including PGE2, modulate the interaction between T cells and antigen-presenting cells such that suppressor/effector T cells are preferentially activated.'^ Eicosanoids can also function as chemotactic factors for T cells. Keratinocytes also elaborate factors distinct from eicosanoids, IL-1, and IL-8 that are chemotactic for T cells.'^ Whether these play a role in contact dermatitis remains to be elucidated.
Another immunocompetent epidermal cell type is the dendritic bone marrow-derived Langerhans cell, which comprises 2% to 5% of the total epidermal cell population.^^ While they represent only a minority of the epidermal cell population, they are the only constitutively present antigen-presenting cell type of the human epidermis.^''•^^ Suprabasally localized in the epidermis, it was the first resident epidermal cell type with immune function to be described. Ultrastructurally, Langerhans cells are distinguished from other cell types by their intracytoplasmic Birbeck's granules. They express CDl, a major histocompatibility complex (MHC) class I-like molecule and human leukocyte antigen (HLA)-DR, an MHC class II molecule.^^"^" CDl may be involved in receptor-mediated endocytosis, while HLA-DR is probably involved in presentation of the processed antigen to CD4^ T cells.
Dermal Immunocompetent Cells
Fibroblasts, endothelial cells, dermal antigen-presenting cells, mast cells, and lymphocytes are the immunocompetent cell types of the dermis.
Structurally, the dermis consists of a framework of collagen, elastic, and reticular fibers embedded in a matrix of glycosaminoglycans. These elements are all produced by the fibroblast. In addition, fibroblasts can be stimulated by IL-1 to produce prostaglandins, which may be involved in inflammation.-" Thus, besides producing the dermal framework, fibroblasts also may function in immune reactions.
The dermal vessels are lined by endothelial cells that constitutively express intercellular adhesion molecule-1 (ICAM-1).^^ This molecule is a natural ligand for lymphocyte function-associated antigen-1 (LFA-1 ),^^ a glycoprotein expressed on the surface of most leukocytes. Thus, a molecule expressed by endothelial cells is the natural binding site for a molecule expressed by many leukocytes. These adhesion molecules are recognized to be important for cell-cell interactions; upregulation of their expression by cytokines may be involved in the migration of leukocytes from the vessels into the dermis and the epidermis.
Possible antigen-presenting cells of the dermis are the dermal dendrocytes. They are HLA-DR"^ and are localized around the papillary vascular plexus. These cells may be analogous to dermal Ia^ cells of the murine system, which have the capacity to present antigens to T lymphocytes.^"* Another dermal cell type, the mast cell, can be stimulated by the immune system to release histamine and platelet-activating factor.^^'^* Histamine generates prostaglandins, stimulates suppressor lymphocytes, and is a potent vasoconstrictor.^^'^^ Platelet-activating factor is a potent stimulus for leukocyte migration and the production of lipoxygenase products of arachidonic acid metabolism.
•'^ These products are potent mediators of inflammation.
The few lymphocytes present in the dermis are mainly T cells and include virtually no B cells. These cells are found around the postcapillary venules of the papillary vascular plexus and most of them express HLA-DR and IL-2 receptors, which indicates that they are in a functionally activated state. T cells can be divided into two functionally distinct subsets distinguished by their expression of the CD4 or the CD8 molecule. CD4''^ T cells interact with MHC class IIbearing cells (antigen-presenting cells), while CD8^ T cells interact with MHC class I-bearing cells (all nucleated cells). CD4^ T cells can be further divided into helper/inducers, which express high levels of 4B4, and suppressor/inducers, which express high levels of 2H4. In normal dermis, the CD4+ and CD8"^ T-cell subsets are evenly distributed."" However, of the CD4^ T cells, the majority are 434"^ (helper/inducer T lymphocytes), and the minority are 2H4+ (suppressor/inducer T lymphocytes).'*" In contrast, the CD4+2H4+ and the CD4^4B4^ lymphocyte subpopulations in peripheral blood are the same size. Activated T lymphocytes elaborate a variety of lymphokines potentially important for contact dermatitis reactions, including IL-2,'" gamma interferon,''Î L-S,"^'"*" ^-4,"= and GM-CSF.'*'^''^ As stated previously, T lymphocytes can be activated through both antigen-dependent and -independent pathways. Antigen-dependent T-cell activation is critical to the initiation of allergic contact hypersensitivity reactions and is described below.
Pathogenic Mechanism of Aiiergic Contact Dermatitis
Most allergens are low molecular weight, highly reactive, lipid-soluble haptens that must be conjugated to an epidermal carrier protein before they can function as complete antigens. Antigen-specific activation of T cells is critically dependent on antigen-presenting cells, which express MHC class II molecules such as HLA-DR or HLA-DQ. Langerhans cells, which express CD 1 and HLA-DR (ie, CDrDR+), are the only cells in normal human epidermis capable of presenting antigens to T cells. CD 1 ^DR^ Langerhans cells can process and present hapten/carrier conjugates into an immunogenic form recognizable by CD4^ inducer T lymIt is thought that Langerhans cells internalize antigen by pinocytosis. The pinocytotic antigen-containing vesicle then fuses with a lysosome, creating a phagolysosome. Enzymes within the phagolysosome partly digest the antigen into immunogenic antigen fragments, termed processed antigen. It seems that these combine with cytoplasmic HLA-DR molecules and are transported to the cell surface membrane, where they are coexpressed (Fig. 1 ). CD4^ T cells cannot recognize antigen alone; only when presented in the context of MHC class II molecules is the antigen recognized.
The T-cell structure responsible for antigen recognition is termed the T-cell receptor and consists of an alpha/beta peptide heterodimer that is rearranged during thymic development. Rearrangement generates a unique antigen-specific receptor for each T-cell clone. The signal produced in response to antigen recognition by the T-cell receptor is transmitted to the interior of the cell via the transduction peptide CD3, which is complexed with the T-cell receptor. The resulting activation of the T cell causes the T cell to express IL-2 receptor on its surface and to release IL-2 and other lymphokines. Binding of IL-2 to the IL-2 receptor induces T-cell proliferation. Thus, lL-2 functions as an autocrine T-cell growth factor. Such activation results in the generation of effector T cells capable of mediating delayed-type hypersensitivity reactions"*^"^' as well as the generation of cytotoxic T cells directed against haptenized epidermal cells.^"'^^ However, immunoregulatory suppressor T cells that down-modulate the effector responses are also induced.^''" The net effect of the immune response is therefore dependent on the balance between effector and regulatory cells.
Except when very potent allergens are involved, the primary sensitizing event does not normally result in clinical skin lesions. This is probably due to the low number of responder T lymphocytes present. However, subsequent rechallenges resulting in clonal T-cell expansion and representation ofthe antigen to primed (memory) T cells may result in cytokine release and cytotoxicity, generating an acute contact dermatitis lesion. The sensitization and elicitation phases of the immune response in allergic contact dermatitis are described in more detail below.
Sensitization in Aiiergic Contact Dermatitis
Following sensitization in animals, Langerhans cells have been found in the dermal lymphatics and in the draining regional lymph nodes.^'' This may indicate that Langerhans cells take up antigen in the skin and migrate to the paracortical area of the regional lymph node, where they present the processed antigen to unprimed T cells with specificity for that particular antigen.^^ This results in the generation and expansion of antigen-specific memory T cells (ie, primed T cells). which then distribute throughout the circulation and home to the site of antigen challenge (Fig. 2) . The Langerhans cell's role in the induction of contact hypersensitivity is highlighted by studies performed in Langerhans cell-depleted skin, such as murine tail skin, UV-irradiated skin, or in epidermal cell suspensions depleted of Langerhans cells by UV irradiation. Sensitization in these systems results in the development of antigen-specific tolerance. ^^~' '° Peroral or intravenous administration of the allergen may also result in antigen-specific tolerance. Thus, it appears that when antigen is presented by non-Langerhans antigen-presenting cells, T suppressor lymphocytes are activated, and tolerance, rather than contact hypersensitivity, results.
Elicitation of Allergic Contact Dermatitis
Rechallenge of the skin will result in representation of the antigen by Langerhans and possibly non-Langerhans antigen-presenting cells to primed T cells. This may take place in the epidermis, the dermis, or in the regional draining lymph nodes, and results in T-cell activation. As stated previously, these activated T cells release a variety of lymphokines, such as IL-2,'" gamma-interferon,''^ GM-CSF,"'^''^ IL-3,''3''"* and IL-4.''^ These lymphokines have a variety of immunologic effects that are potentially important in contact dermatitis.
Gamma-interferon released from lesional activated T cells upregulates the expression of intercellular adhesion molecules, such as ICAM-1, on both keratinocytes and endothelial cells.^'''^'-^^ This is thought to be important for the recruitment of cells that express LFA-1, such as T cells and other leukocytes,^"* which then participate in the ongoing immune response.
Interleukin-3 is present in the early phases of a delayed-type hypersensitivity reaction^^ and is released from activated T cells. It induces mast cell proliferation and is involved in the activation of monocytes.
Mast cells and monocytes are present in increased numbers in contact hypersensitivity reactions. Furthermore, IL-3 and GM-CSF, as well as other lymphokines, may enhance keratinocyte proliferation.^"* Thus, these activated T-cell products may be partially responsible for the epidermal hyperplasia seen in contact dermatitis (Fig. 3) .
In addition to lymphokines released by activated T cells, other cytokines are important in the elicitation of contact dermatitis. Interleukin-1, a cytokine released from Langerhans cells, macrophages, and keratinocytes has been found in increased amounts in the epidermis during an allergic patch test reaction.'^ The binding of IL-1 to keratinocyte IL-1 receptors stimulates keratinocyte growth and may thereby contribute to the epidermal hyperplasia seen in contact hypersensitivity."--^ Interleukin-1 may also stimulate keratinocyte release of GM-CSF, which may result in the expansion of the Langerhans cell population.^^ Indeed, the number of Langerhans cells is increased in allergic contact dermatitis.""*^"
In allergic skin reactions, CD1"DR^ non-Langerhans antigen-presenting cells appear in the epidermis.^'-^'''' These cells are able to activate autologous T cells and are responsible for up to 50% of the total epidermal T-cell activating capacity during the allergic reaction.*** The function of these antigen-presenting cells is unknown. However, they may be analogous to HLA-DR IL-2 Figure 3 . Elicitation, the efferent phase of the immune response in allergic contact dermatitis. Presentation of antigen in the skin by Langerhans and other antigen-presenting cells to primed (memory) T cells results in T-cell activation and expansion and lymphokine release. The antigen is presented in the context of HLA-DR class II MHC molecules to the T-cell receptor, a heterodimer composed of an alpha and beta peptide chain. The signal is transmitted from the T-cell receptor to the interior of the cell via a transduction peptide termed CD3. Activation causes the T cells to release lymphokines including IL-2, IL-3, gamma-IFN and GM-CSF and to express IL-2 receptors. IL-2 binding to the IL-2 receptor induces T-cell proliferation. IL-.3 and GM-CSF may induce keratinocyte proliferation and may be responsible for the epidermal hyperplasia seen in contact dermatitis. Gamma-IFN and tumor necrosis factor induce keratinocyte expression of intercellular adhesion molecules (e.g., ICAM-1), whereas only gamma-interferon induces HLA-DR. ICAM-1 is the natural ligand for LFA-1, a molecule expressed by many leukocytes that is important for cell-cell interaction. ICAM-1 also may be responsible for compartmentalization of leukocytes in the skin during a contact dermatitis reaction. Keratinocytes that express HLA-DR may, under certain circumstances, present protease-digested antigen fragments to already primed T cells, thereby enhancing the ongoing immune response. HLA-DR^ keratinocytes also may be a target for certain cytotoxic effector T cells. Cytokines such as IL-1, IL-6, and GM-CSF released from activated keratinocytes can stimulate activation and proliferation of T cells and, in the case of GM-CSF, Langerhans cells. Monocytes and mast cells also may be activated and may release proinflammatory mediators. Spongiosis, cell injury, and cell death are the combined effect of these interactions, and the clinical picture of allergic contact dermatitis results.
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Keratinocytes in allergic and irritant skin reactions express both ICAM-1 and HLA-DR. These immunocompetent surface molecules are probably induced by lymphokines such as gamma-interferon released from local T cells.2'''^'-<'2<'9-^' HLA-DR+ keratinocytes are, under certain circumstances, able to present antigenic peptide fragments to primed (memory) T cells.'^ Additionally, HLA-DR^ keratinocytes can also act as targets for MHC class II restricted cytotoxic T-cell clones.^^ Thus, HLA-DR expression may allow keratinocytes to participate in immunologic responses, such as antigen presentation and cytotoxicity, that result in enhancement of the immune reaction. However, HLA-DR"^ keratinocytes may also be involved in the development of antigen-specific tolerance. This aspect of HLA-DR^ keratinocytes is discussed in an upcoming section.
Regulation of the Inflammatory Response in Allergic Contact Dermatitis
Multiple cell types, factors, and cytokines are involved in regulation of the inflammatory response in allergic contact dermatitis. Inhibitory and stimulatory factors interact to determine whether the immune response is up-or downregulated (Fig. 4) . Normally, stimulatory signals provided by Langerhans cells are counteracted by inhibitory signals provided by keratinocytes such that an immune response is not initiated. Antigens or irritants can upset this balance, resulting in the development of contact dermatitis.
Sensitization results in antigen-specific activation of both effector and suppressor pathways. The net effect is dependent on the physical and chemical properties of the antigen as well as the route of administra- Although the alloantigen-presenting capacity of HLA-DR+ keratinocytes is weak, the keratinocytes can, under certain circumstances, present antigens leading to T-cell activation and possibly also lymphokine release, and thus potentiate an ongoing immune response. On the other hand, the epidermis also contains the capacity to downregulate the immune response. UV-induced nonLangerhans CDl OKM5^DR* antigen-presenting cells seem to preferentially activate suppressor pathways. Furthermore, HLA-DR+ keratinocytes can present antigen to unprimed T cells, resulting in antigen-specific tolerance to subsequent antigen presentation by Langerhans cells. A variety of T-cell inhibitory cytokines may be released from keratinocytes in vitro including KLIF, PGE2, TGF-beta, and ELDIF. The mechanism responsible for regulation of the release of stimulatory and inhibitory cytokines from the keratinocytes is unknown. In the murine system, IJ* antigen-presenting cells (APC) and Thy 1 * dendritic T cells also contain the capability to downregulate immune responses. Clear human analogues to the two murine cell types, however, await identification. tion. High concentrations of antigen induce antigenspecific unresponsiveness through activation of antigen-specific suppression. This suppression is transferrable through donor T lymphocytes to syngeneic recipients.'^ Activation of antigen-specific suppressor T ceils in this system may be due to systemic antigen absorption following overloading of the skin by antigen, thus bypassing epidermal Langerhans cells. As mentioned earlier, antigen administration that bypasses the Langerhans cells results in the activation of antigen-specific suppressor T cells, which can downregulate the immune response.^"'**'^ This mechanism also may be responsible for the relative rarity df contact dermatitis in workers exposed to large allergen doses, such as nickel workers. It has also been used by Kligman and others to treat patients with poison ivy dermatitis with oral urushiol extract. ^"^ However, urushiol extract desensitization is short-lived and the side effects are troublesome.
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The type of antigen is also important in sensitization. For example, application to the skin of 2,4-dinitrothiocyanatebenzene (DNTB), an antigen that crossreacts with 2,4-dinitrofluorobenzene (DNFB), results in suppressor T-cell activation that downregulates subsequent reactions to DNFB.'^''** As mentioned earlier, cytokines released from activated T cells induce keratinocyte HLA-DR expression, which may allow them to enhance the immune reaction. Presentation of antigen by HLA-DR^ keratinocytes to unprimed T cells, however, results in the development of antigen-specific unresponsiveness to later antigen presentation by Langerhans cells. Thus, HLA-DR^ keratinocytes also may downregulate the inflammatory response (Fig. 4) .^'' Cytokines derived from keratinocytes can exert inhibitory or stimulatory effects on T cells, and their balance may be a critical factor determining T-cell activation state. Keratinocyte factors that downregulate
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Vol. 30 T-cell responses include prostaglandins,**" eicosanoids,'^ epidermal cell-derived lymphocyte differentiation inhibiting factor (ELDIF),'° keratinocyte lymphocyte inhibitor factor (KLIF),'^ and transforming growth factor-beta (TGF-beta) (Fig. 4) .'B one marrow-derived cells capable of providing downregulating signals also exist within the epidermis. In the murine system, Granstein has demonstrated an IJ^, UV-resistant, antigen-presenting cell type that activates suppressor T-cell pathways (Fig. 4) .^''^^ Another bone marrow-derived dendritic cell type distinct from Langerhans cells also is constitutively present in murine epidermis.'^^'^^^ These cells lack class II MHC molecules but express Thy-1 and T-cell receptors composed of gamma and delta chains.**^"**"* Thy 1^ dendritic intraepidermal gamma/delta T-cell receptor-positive cells exert a negative effect on the immune response, resulting in the induction of antigen-specific tolerance (Fig. 4) .^°D espite intensive research, clear human analogues to these cell types have not been found. However, bone marrow-derived, non-Langerhans, antigen-presenting cells do appear in the course of a contact dermatitis reaction and may be involved in suppressor T-cell activation.''^*'** This hypothesis is supported by the observation that these non-Langerhans cells demonstrate the OKMrOKM5"^ phenotype.*"** This phenotype is analogous to a minor (<5%) subset of blood monocytes uniquely capable of activating autoreactive immunoregulatory T cells capable of immune downregulation."-"
Pathogenic Mechanism of Irritant Contact Dermatitis
Allergic and irritant dermatitis share many clinical and histopathologic features and are often difficult to distinguish; however, clear differences exist. For example, although both responses are characterized by a similar distribution of T-cell subsets, the number of CDlL angerhans cells is decreased in irritant reactions, whereas it is increased in allergic reactions.'''*''''**'^'' These findings are highlighted by our observation of decreased epidermal antigen-presenting cell capacity to activate T cells following irritant challenge and increased epidermal antigen-presenting cell function following allergic challenge.'''''** While allergic contact dermatitis is a classic example of antigen-dependent T-cell activation, the pathogenic mechanism of irritant contact dermatitis is not known. We think, however, that the decreased capacity of irritant-challenged epidermis to activate T cells suggests that antigen-dependent pathways are not critical for the immunologic response in irritant contact dermatitis. Thus, we propose that in irritant contact dermatitis, cytokines released from mechanically or chemically injured keratinocytes induce T-cell activation independent of antigen ( Fig. 5) , and that the initiating event in irritant-induced contact dermatitis is unknown but may be the release of eicosanoids or other chemoattractants by injured keratinocytes.
This hypothesis is supported by the observation that epidermally derived chemoattractants and T-cell growth enhancing factors are present in irritant skin reactions."'^" Following T-cell activation and lymphokine release, the cellular immunologic event and the regulation of the inflammatory response in both allergic and irritant contact dermatitis seem to be similar.
Mechanism of Action of Therapeutic Agents in the Treatment of Contact Dermatitis Cortioosteroids
Corticosteroids have a profound effect on the immune system. Topically, they inhibit both the afferent and the efferent limb of the allergic contact dermatitis reaction.''^'"' Steroids inhibit antigen-specific lymphocyte activation and proliferation.'' This is probably due to direct effect on both antigen-presenting cells and T cells. Topical application of steroids to the skin depletes Langerhans cells of CDl and HLA-DR molecules, abrogating their antigen-presenting function.""*-'™ Corticosteroids also block T-cell release of IL-2, thereby inhibiting T-cell proliferation."*' These immunomodulatory effects turn off the ongoing immune response in contact dermatitis and are responsible for the therapeutic effects of corticosteroids in the treatment of contact dermatitis.
Ultraviolet Radiation
Ultraviolet light also exerts its therapeutic effects on contact dermatitis through the immune system. Ultraviolet exposure of the skin abrogates Langerhans cell function and induces the appearance of bone marrowderived antigen-presenting cells, which can activate T suppressor cells.
Ultraviolet exposure of the skin results in the disappearance of Langerhans cell surface molecules (CD 1 and HLA-DR), and thus eliminates their antigen-presenting function (Fig. e) .""'"^ However, HLA-DR"*^, bone marrow-derived, antigen-presenting melanophages appear in the epidermis in response to the irradiation.'"^"""" These non-Langerhans antigen-presenting cells (non-LC APC) are ultrastructurally distinct from Langerhans cells in that they lack Birbeck's granules and express melanosomes within phagolysosomes. Phenotypically, they lack the CDl determinant expressed on epidermal Langerhans cells and bear the OKM1^OKM5^ phenotype, demonstrating analogy to a minor subpopulation of antigen-presenting cells in the blood'' that can activate immunoregulatory T cells.^-' These non-LC APC are capable of activating both antigen-specific CD4+2H4" T cells, which provide help for B-cell immunoglobulin production, as well as autoreactive CD4^2H4^ T cells, which induce the maturation of suppressor T cells.'°^'""' However, CD4"^2H4"*^ suppressor/inducer T-cell activation dominates, and the net functional effect is therefore the induction of suppression (Fig. 6 ).'°'"°I n the murine system, sensitization through skin previously exposed to low doses of UV radiation results in antigen-specific unresponsiveness. This local effect is due to the appearance of antigen specific T suppressor cells that operate at the afferent limb of the immune response to prevent the activation of effector cells for delayed-type hypersensitivity.''' High doses of UV radiation, however, result in systemic suppression of the immune response, where sensitization through either exposed or unexposed skin results in induction of antigen-specific tolerance.^**"^ Although the cellular mechanisms responsible for induction of these suppressor T cells are not clear, UV-resistant, IJ-restricted, antigen-presenting cells or Thyl^ dendritic epidermal cells that express gamma-delta T-cell receptors may be important. 81.82.90 Ultraviolet-induced epidermal CDl OKM5^DR+, non-Langerhans, antigen-presenting cells of the human system may be the functional analogue to epidermal cells in the murine system that provide antigen-specific downregulating signals.
Cyclosporine A Cyclosporine A is a cyclic undecapeptide that causes suppression of immune stimulation both in vivo and in vitro. Systemic cyclosporine A is very efficient in the treatment of psoriasis and will probably demonstrate efficacy in all skin diseases dependent on activated T cells. "^ Cyclosporine A has differential effects on T lymphocyte subsets. Helper-inducer T cells are sensitive to very low doses of cyclosporine A, and decreased production of lymphokines such as IL-2, IL-4, gamma-interferon, and tumor necrosis factor results.'"*""^ The maturation and generation of cytotoxic T cells are also affected by low doses cyclosporine A.'" In contrast, suppressor T cells are insensitive to low doses of cyclosporine A."'*'"* These immunologic effects indicate that cyclosporine A may be useful in the treatment of contact dermatitis. Accordingly, animal studies have demonstrated that systemic cyclosporine A blocks the effector function of delayed-type hypersensitivity T cells, although the priming of these cells is cyclosporine A-insensitive."' Topical cyclosporine A inhibits the elicitation of contact hypersensitivity in guinea pigs.''° However, application of topical cyclosporine A to human skin has only minimal effect, probably due to either lack of absorption or epidermal/dermal inactivation of the drug.'"' Systemic cyclosporine A may play a role in the treatment of severe recalcitrant contact dermatitis; however, due to its nephrotoxicity, widespread use of this agent in contact dermatitis awaits an efficient topical formulation.
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